Bristol Myers 3rd Quarter Revenue Rises on Strong Growth Drug Sales
Yahoo Finance ·
Bristol Myers Squibb reported that its third-quarter total revenue climbed 7 percent to reach $13.1 billion, largely propelled by its emerging product lineup. The company's Growth Portfolio advanced 12 percent to $7.7 billion, accounting for nearly the entire top-line expansion and contributing an additional $830 million compared to the previous year. Key contributors included Opdivo Qvantig, Breyanzi, and several other therapeutics, demonstrating a diversified revenue base. Earnings per share stood at $1.05 on a GAAP basis and $1.35 on an adjusted basis, with the adjusted metric declining 17 percent from $1.63 due to expenses related to pipeline acquisitions. Meanwhile, the Legacy Portfolio ticked up 1 percent, sustained primarily by Eliquis defying generic pressure. Buoyed by these developments, management elevated its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion. Company shares remained essentially unchanged during midday trading following the earnings announcement.
AI 시장 분석
Bristol-Myers Squibb's (BMY) Q3 revenue rose 7% to $13.1 billion, driven by a 12% growth in its new drug portfolio. Adjusted EPS fell 17% to $1.35 due to pipeline acquisition costs. The company raised its 2026 revenue guidance, signaling a potential shift toward new drug-driven growth. Investors should watch whether the new drug portfolio successfully diversifies against older blockbuster patent expirations.
상승 영향
- Biotechnology — New drug portfolio revenue grew 12% to $7.7 billion, driving overall growth and leading to an upward revision of the 2026 guidance.
하락 영향
- Biotechnology — Adjusted EPS fell 17% year-over-year due to pipeline acquisition costs, putting pressure on short-term profitability.
DYAX 전담 분석
BMY's Q3 results show a strong causal relationship, with new drug portfolio revenue hitting $7.7 billion to drive overall revenue growth. The drop in adjusted EPS stems from investments for future growth, proving it is not a weakening of core business fundamentals.
In the bullish scenario, a stock rebound is expected through the acceleration of the new drug portfolio and achievement of 2026 guidance, while the bearish scenario faces risks from accelerated generic erosion of older drugs and acquisition cost burdens. Investors should closely monitor sales trends of major new drugs like Opdivo and patent expiration defense metrics.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 30% · Bearish (Short) 70%
405 participants
Related News
- Amazon 3Q Report Reveals Dual Miss on Sales and Earnings Expectations
- MetLife CEO and CFO Set to Present at Upcoming J.P. Morgan Financials Conference
- Intel Shares Plunge 20% on Disappointing Fourth-Quarter Outlook
- Intel Shares Plummet Following Weak Fourth-Quarter Guidance
- Michael Burry Traces Anthropic's Capital Flow to Reveal Familiar Entities
- Equities Snap Winning Streak as Alphabet Suffers Record Post-Earnings Plunge
